Core Viewpoint - Jinkai Biotechnology (301509.SZ) expects a significant increase in net profit for 2025, driven by improved terminal demand and order delivery pace [1] Financial Performance - The company anticipates a net profit attributable to shareholders ranging from 92 million to 116 million yuan, representing a year-on-year growth of 138.28% to 200.45% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 72 million and 91 million yuan, indicating a year-on-year increase of 314.69% to 424.12% [1] Operational Factors - The increase in delivered orders during the reporting period is attributed to the recovery in terminal demand and the rhythm of customer order deliveries [1] - The overall gross profit margin has improved due to the impact of the product structure of delivered orders [1]

北京商报讯（记者 丁宁）1月23日晚间，金凯生科（301509）发布2025年业绩预告显示，预计2025年归 属净利润约为0.92亿元至1.16亿元，同比增长138.28%至200.45%。 金凯生科表示，受终端需求回暖及客户订单交付节奏影响，报告期内公司交付订单增加；同时受交付订 单产品结构影响，公司总体毛利率有所提高。以上综合因素导致公司2025年度业绩同比出现较大幅度提 升。 ...

Group 1 - New Strength Union (新强联) expects a net profit attributable to shareholders of 780 million to 920 million yuan for 2025, representing a year-on-year growth of 1093.07% to 1307.21, driven by the recovery in wind power demand and increased market share due to technological advantages [1] - Yongchuang Intelligent (永创智能) forecasts a net profit of 128 million to 155 million yuan for 2025, an increase of 721.57% to 894.86%, attributed to improved production and delivery management, along with a favorable product mix that enhanced gross margins [3] - Lianhua Technology (联化科技) anticipates a net profit of 350 million to 420 million yuan for 2025, reflecting a growth of 239.35% to 307.22%, supported by higher capacity utilization and foreign exchange gains from overseas subsidiaries [7] - Jinkai Biotechnology (金凯生科) projects a net profit of 92 million to 116 million yuan for 2025, indicating a year-on-year increase of 138.28% to 200.45%, driven by increased order deliveries and improved product mix affecting overall gross margins [8] - Shengen Technology (神工股份) expects a net profit of 90 million to 110 million yuan for 2025, a growth of 118.71% to 167.31%, due to the recovery in the global semiconductor market and increased demand for key materials in domestic markets [9]

Group 1 - The company, Jinkai Biotechnology, announced an expected net profit attributable to shareholders for the year 2025 ranging from 92 million to 116 million yuan, representing a year-on-year growth of 138.28% to 200.45% [2]

受终端需求回暖及客户订单交付节奏影响，报告期内公司交付订单增加;同时受交付订单产品结构影 响，公司总体毛利率有所提高。 金凯生科（301509）(301509.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润9200 万元至1.16亿元，同比增长138.28%至200.45%;扣除非经常性损益后的净利润7200万元至9100万元，同 比增长314.69%至424.12%。 ...

受终端需求回暖及客户订单交付节奏影响，报告期内公司交付订单增加;同时受交付订单产品结构影 响，公司总体毛利率有所提高。 智通财经APP讯，金凯生科(301509.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润 9200万元至1.16亿元，同比增长138.28%至200.45%;扣除非经常性损益后的净利润7200万元至9100万 元，同比增长314.69%至424.12%。 ...

Core Viewpoint - KingKaiser Biotechnology (301509.SZ) forecasts a net profit attributable to shareholders of 92 million to 116 million yuan for the year 2025, representing a year-on-year growth of 138.28% to 200.45% [1] Group 1 - The increase in net profit is attributed to a recovery in end-user demand and the delivery schedule of customer orders, leading to an increase in order deliveries during the reporting period [1] - The overall gross profit margin improved due to the impact of the product mix of delivered orders [1] - These combined factors resulted in a significant year-on-year increase in the company's performance for 2025 [1]

（文章来源：每日经济新闻） 每经AI快讯，金凯生科(301509)1月23日发布业绩预告，预计2025年归母净利9200万元~1.16亿元，同比 增长138.28%~200.45%。受终端需求回暖及客户订单交付节奏影响，报告期内公司交付订单增加；同时 受交付订单产品结构影响，公司总体毛利率有所提高。 ...

证券代码：301509 证券简称：金凯生科 公告编号：2026-001 金凯（辽宁）生命科技股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、本期业绩预计情况 二、与会计师事务所沟通情况 本次业绩预告相关数据是公司财务部门初步测算结果，未经注册会计师预审 计。公司已就业绩预告有关事项与年报审计会计师事务所进行了预沟通，公司与 会计师事务所在本次业绩预告方面不存在分歧。 三、业绩变动原因说明 受终端需求回暖及客户订单交付节奏影响，报告期内公司交付订单增加；同 时受交付订单产品结构影响，公司总体毛利率有所提高。以上综合因素导致公司 2025 年度业绩同比出现较大幅度提升。 四、其他相关说明 本次业绩预告数据是公司财务部门初步测算的结果，具体财务数据将在公司 2025 年年度报告中详细披露，敬请广大投资者理性投资，注意风险。 1 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为正值且属于同向上升 50%以上情形。 单位：万元 | 项 | 目 | 本报告期 | ...

（文章来源：证券日报） 证券日报网讯 1月21日，金凯生科在互动平台回答投资者提问时表示，截至2026年1月20日，公司股东 数为14722户。 ...